Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00423657
View directory record Official record
Conditions
Bacterial Infections
Interventions
ceftaroline, vancomycin plus aztreonam, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
17
States / cities
Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Phase 3 Interventional

Nebulized Ketamine for the Treatment of Major Depressive Disorder

NCT06752759
View directory record Official record
Conditions
Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
Interventions
nebulized ketamine, nebulized midazolam
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

NCT00036088
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
25
States / cities
El Centro, California • Glendale, California • Sherman Oaks, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862
View directory record Official record
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional Results available

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

NCT03713320
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
Cobomarsen, Vorinostat
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional Results available

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

NCT02162979
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sildenafil, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

NCT01187901
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Erlotinib, Sulindac, Placebo A, Placebo B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 69 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 21, 2026, 7:22 PM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 21, 2026, 7:22 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

NCT07118592
View directory record Official record
Conditions
Hypertension (HTN), Cardiometabolic Diseases
Interventions
Low Salt Diet, High Salt Diet, Saline Infusion
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

NCT03565900
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
3 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra Oral Application (IOA) Testing Study of a Stannous Toothpaste

NCT07419672
View directory record Official record
Conditions
Dental Caries
Interventions
Negative Control Treatment Slurry (Fluoride-Free), Active Comparator Fluoride Treatment (0.454% SnF), Test Fluoride Treatment (0.454% SnF) (Investigational Toothpaste)
Drug
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Noblesville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Not applicable Interventional

Reducing Suicide Risk in Older Veterans Using Problem Solving Therapy

NCT04763330
View directory record Official record
Conditions
Suicidal Ideation, Depressive Disorder, Anxiety Disorders, Post Traumatic Stress Disorder
Interventions
Enhanced Usual Care (EUC), Problem Solving Therapy (PST) plus EUC
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Withdrawn Phase 2 Interventional

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

NCT04807829
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Nabilone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

NCT01850524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 21, 2026, 7:22 PM EDT
Withdrawn Not applicable Interventional

Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.

NCT02863822
View directory record Official record
Conditions
Dyspepsia, Dietary Modification
Interventions
Low FODMAP Diet, Choose My Plate Diet
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wellbeing, Stress Reduction and Social Cognition

NCT04494737
View directory record Official record
Conditions
Cognitive Function 1, Social
Interventions
Active Comparator: Program 1, Active Comparator: Program 2
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
26
States / cities
Duarte, California • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Radiofrequency Microneedling for Facial Rejuvenation

NCT06157853
View directory record Official record
Conditions
Photoaging, Wrinkle
Interventions
Radiofrequency Microneedling, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

Bexagliflozin Efficacy and Safety Trial

NCT02558296
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
40 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
66
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Azusa, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of a DeskCycle to Reduce Sedentary Behavior During the Workday

NCT05412797
View directory record Official record
Conditions
Chronic Disease, Reduction, Weight
Interventions
Cycling/Using a DeskCycle, Regular activities
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kent, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

NCT00353587
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MBX-102, Placebo, Actos
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Jonesboro, Arkansas • Buena Park, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Subjects With Distal Renal Tubular Acidosis

NCT03644706
View directory record Official record
Conditions
Distal Renal Tubular Acidosis
Interventions
ADV7103, Placebo
Drug
Lead sponsor
Advicenne Pharma
Industry
Eligibility
6 Months to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Not yet recruiting Early Phase 1 Interventional

Cholinergic Enhancement of Theta

NCT07228338
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
Interventions
COBENFY KarXT (50/20 mg), Control
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 7:22 PM EDT